阿伐斯汀联合芪风颗粒治疗慢性荨麻疹的疗效观察

Clinical Efficacy of Acrivastine Combined with Qifeng Granules on Chronic Urticaria

目的:观察阿伐斯汀联合芪风颗粒治疗慢性荨麻疹的临床疗效和安全性。方法:130例慢性荨麻疹患者随机分为观察组与对照组,对照组采用阿伐斯汀胶囊治疗,观察组采用阿伐斯汀胶囊联合芪风颗粒,均治疗4周。对比分析两组瘙痒情况,风团大小、数目等临床症状改变,以及疗效等情况。结果:治疗后1个月和3个月,观察组风团数目、风团大小、发作持续时间等症状评分,以及每周发作次数、VAS评分、复发率等指标明显优于对照组(P<0.05);观察组总有效率为92.5%,明显高于对照组的73.0%(P<0.05);两组药品不良反应发生情况差异无统计学意义(P>0.05)。结论:阿伐斯汀联合芪风颗粒治疗慢性荨麻疹疗效确切,能有效改善患者症状,减少复发,值得临床推广应用。

Objective： To observe the clinical efficacy and safety of acrivastine combined with Qifeng granules on chronic urticari- a. Methods： Totally 130 patients with chronic urticaria were randomly divided into the observation group and the control group. The patients in the control group were treated with acrivastine, while the patients in the observation group were treated with acrivastine com- bined with Qifeng granules. The duration of treatment was 4 weeks. The clinical symptoms, including itching and size and number of wheals, and the efficacy were analyzed and compared between the two groups. Results： After the 1-month and 3-month treatment, the number and size of wheals, attacking duration, times of attacking per week, VAS score and relapse rate in the observation group were significantly better than those in the control group （P 〈0.05）.. The effective rate of the observation group （92.5%） was significantly higher than that in the control group （73.0% , P 〈 0.05 ）. There was no significant difference in adverse reactions between the obser- vation group and the control group （P 〉 0.05 ）. Conclusion： Aerivastine combined with Qifeng granules in the treatment of chronic ur- ticaria can effectively improve the clinical symptoms and reduce the relapse, which is worthy of clinical promotion.